Programmable Bispecific Nano-immunoengager That Captures T Cells and Reprograms Tumor Microenvironment

[Image: see text] Immune checkpoint blockade (ICB) therapy has revolutionized clinical oncology. However, the efficacy of ICB therapy is limited by the ineffective infiltration of T effector (T(eff)) cells to tumors and the immunosuppressive tumor microenvironment (TME). Here, we report a programmab...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lu, Bo, Ruonan, Wu, Yi, Li, Longmeng, Zhu, Zheng, Ma, Ai-Hong, Xiao, Wenwu, Huang, Yanyu, Rojalin, Tatu, Yin, Xingbin, Mao, Chunping, Wang, Fengyi, Wang, Yongheng, Zhang, Hongyong, Low, Kelmen E., Lee, Kiana, Ajena, Yousif, Jing, Di, Zhang, Dalin, Baehr, Christopher M., Liu, Ruiwu, Wang , Lei, Li , Yuanpei, Lam, Kit S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479133/
https://www.ncbi.nlm.nih.gov/pubmed/35926215
http://dx.doi.org/10.1021/acs.nanolett.2c00582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479133/
https://www.ncbi.nlm.nih.gov/pubmed/35926215
http://dx.doi.org/10.1021/acs.nanolett.2c00582

Ejemplares similares